Skip to content

Government Incentives Reduce Drug Imports, Expand Local Production

By News Analysis India · · 1 min read

Recent fact‑sheet data show that India's Production Linked Incentive (PLI) framework is delivering measurable cuts in pharmaceutical import dependency. By earmarking billions of rupees for strategic product lines, the government is prompting domestic firms to invest in full‑scale manufacturing.

The bulk‑drug PLI, approved with a ₹6,940 crore budget, concentrates on 41 essential items. Investment to date exceeds ₹5,210 crore, outpacing the original ₹4,330 crore plan. Projects under this scheme have already set up manufacturing for 28 APIs, making it possible to produce key fermentation‑derived drugs such as penicillin‑G, clavulanic acid and rifampicin within Indian borders.

Meanwhile, the pharma‑centric PLI, supported by a ₹15,000 crore allocation, targets high‑value segments including complex generics, biosimilars, patented and non‑patented medicines, orphan drugs, and auto‑immune therapies. Fifty‑five companies, among them 20 MSMEs, have been approved, attracting ₹46,744 crore of actual capital—far above the intended ₹17,275 crore.

The medical‑device incentive, with a ₹3,420 crore pool, offers a five‑year, 5 percent sales incentive for eligible domestic devices. This has enabled Indian manufacturers to launch 57 different high‑end medical equipment lines, ranging from MRI and CT scanners to linear accelerators and heart valves. International players such as GE Healthcare, Siemens, Philips, Varian, Nippo and Omron have responded by establishing or expanding production facilities, further accelerating technology transfer to the Indian market.